FINASTERIDE 5mg

Finasteride (5mg) is a specialized research reagent utilized primarily to investigate the biochemical pathways of 5$\alpha$-reductase inhibition and the regulation of dihydrotestosterone (DHT) signaling. As a potent and selective Type II inhibitor, it is a fundamental tool for exploring androgen-mediated cellular proliferation and follicular dynamics. Dragon Pharma provides Finasteride 5mg at a purity level of 99%+, specifically for use in in-vitro laboratory experiments and preclinical animal models.

Overview

In the realm of endocrinology and dermatological research, Finasteride has become a primary instrument for investigators exploring the conversion of testosterone to its more potent metabolite, DHT. Known scientifically as a 4-azasteroid compound, this reagent offers specific enzymatic blockade that allows for the study of androgen receptor activation at the cellular level. Dragon Pharma provides Finasteride 5mg at a minimum purity of 99%, ensuring that researchers have access to a high-grade Research Compound capable of producing reproducible and accurate data in complex biological models.

As scientific inquiry into benign prostatic hyperplasia (BPH), androgenetic alopecia (AGA), and neurosteroid modulation expands, the need for reliable 5$\alpha$-reductase inhibitors like Finasteride has grown. This expanded profile examines the biochemical characteristics, structural integrity, and multifaceted research applications of Finasteride 5mg.

Molecular Characteristics and Chemical Profile

The structural integrity of Finasteride is what allows it to bind to the Type II 5$\alpha$-reductase enzyme with high affinity. By mimicking the steroid substrate, it prevents the reduction of the double bond between the carbon-4 and carbon-5 positions of the testosterone molecule.

• Chemical Identity: Finasteride
• Molecular Formula: $C_{23}H_{36}N_{2}O_{2}$
• Molecular Weight: 372.54 g/mol
• Purity: >99% (HPLC and Mass Spectrometry verified)
• Form: Crystalline powder / Lyophilized powder
• Manufacturer: Dragon Pharma

Research Applications

The compound is utilized in various scientific investigative domains, including:

• Enzyme Kinetics: Mapping the inhibitory constant ($K_{i}$) and isoenzyme selectivity (Type II vs. Type I).
• Androgen Signaling: Investigating the downstream effects of DHT depletion on nuclear receptor translocation.
• Follicular Biology: Studying the hair follicle miniaturization process and the transition from vellus to terminal hair growth.
• Prostatic Pathophysiology: Assessing cellular apoptosis and proliferation rates in glandular tissue models.
• Neurosteroid Research: Evaluating the impact of 5$\alpha$-reduction inhibition on allopregnanolone levels and GABAergic signaling.

Pathway and Mechanistic Context

The core value of Finasteride 5mg in a laboratory setting is its ability to manipulate the Intracellular Androgen Environment without lowering systemic testosterone levels. In a natural physiological state, the Type II 5$\alpha$-reductase enzyme is primarily expressed in the prostate, seminal vesicles, and hair follicles.

The 5$\alpha$-Reductase Signaling Axis

Upon inhibition of 5$\alpha$-reductase by Finasteride, tissue concentrations of DHT fall by approximately 80–90%. This initiates a global shift in cellular behavior, as DHT possesses a three-fold higher affinity for the androgen receptor than testosterone.

Key Mechanistic Shifts:

• Androgen Response Modulation: Finasteride facilitates the study of androgen-sensitive gene expression by limiting the presence of the most potent endogenous ligand.
• Neuroendocrine Feedback: It provides a framework for investigating the hypothalamic-pituitary-gonadal (HPG) axis response to altered DHT-to-testosterone ratios.
• Tissue Remodeling: Researchers use Finasteride to observe how specialized tissues (like the prostate or dermal papilla) adapt to reduced androgenic stimulus.

Primary Research Applications

1. Urological and Prostatic Research

Finasteride is heavily utilized in studies involving Benign Prostatic Hyperplasia (BPH). Statistics indicate that BPH affects roughly 50% of men by age 50 and up to 90% of men over age 80. Research into racial disparities shows that African American men have a 12% higher risk of developing clinical BPH compared to Caucasian men, often presenting with more severe symptoms and larger prostate volumes. Finasteride provides a unique framework for investigating the reduction of prostatic volume in these varied models.

2. Trichology and Androgenetic Alopecia (AGA)

Known in research circles for its "follicular-restorative" potential, Finasteride is used to observe how hair follicles adapt to a lower-DHT environment. Investigators study changes in the anagen-to-telogen ratio; statistics show AGA affects roughly 50% of Caucasian men by age 50, whereas studies suggest lower prevalence and later onset in East Asian populations (21.3% in men over 50).

3. Oncology and Neuropsychiatry

In metabolic research, Finasteride is studied for its ability to influence the progression of hormone-sensitive cancers. Furthermore, research models focus on how 5$\alpha$-reductase inhibition impacts the central nervous system, specifically regarding the "Post-Finasteride Syndrome" (PFS) model and its effect on neuroactive steroid levels.

Form and Analytical Testing

At Dragon Pharma, the commitment to scientific accuracy begins with a rigorous manufacturing process. Finasteride 5mg is produced under strict laboratory conditions to ensure the compound remains stable and potent.

• Stability and Purity: The compound is optimized for long-term stability, removing impurities that could interfere with steroidogenesis assays.
• Rigorous Analytical Verification: To guarantee a purity level of 99% or higher, every batch undergoes High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS) to confirm that the chemical signature matches the verified Finasteride profile.